Performance of ⁶⁸Ga-DOTA–Conjugated Somatostatin Receptor–Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis

Sangwon Han*[1], Chong Hyun Suh*[2], Sungmin Woo[3], Yeon Joo Kim[4], and Jong Jin Lee[1]

[1]Department of Nuclear Medicine, The Armed Forces Daejeon Hospital, Daejeon, Korea; [2]Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; [3]Department of Radiology, Seoul National University College of Medicine, Seoul, Korea; and [4]Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

We performed a systematic review and metaanalysis of the performance of ⁶⁸Ga-DOTA–conjugated somatostatin receptor–targeting peptide (⁶⁸Ga-DOTA-SST) PET in the detection of pheochromocytomas and paragangliomas (PPGLs). **Methods:** PubMed and Embase were searched until May 8, 2018. We included studies that reported the detection rate of ⁶⁸Ga-DOTA-SST PET in patients with PPGLs. Detection rates were pooled using a random-effects model. Subgroup analyses and metaregression were performed to explore the cause of heterogeneity. **Results:** Thirteen studies were included for qualitative synthesis. Per-lesion detection rates of ⁶⁸Ga-DOTA-SST PET were consistently higher (ranging from 92% to 100%) than other imaging modalities, including ¹⁸F-fluorohydroxyphenylalanine (¹⁸F-FDOPA) PET, ¹⁸F-FDG PET, and ¹²³/¹³¹I-metaiodobenzylguanidine (¹²³/¹³¹I-MIBG) scintigraphy. However, in patients with polycythemia/paraganglioma syndrome, the detection rate of ⁶⁸Ga-DOTA-DOTATATE PET was 35%. Nine studies (215 patients) with no specific inclusion criteria for subtype were quantitatively synthesized. The pooled detection rate was 93% (95% confidence interval [CI], 91%–95%), which was significantly higher than that of ¹⁸F-FDOPA PET (80% [95% CI, 69%–88%]), ¹⁸F-FDG PET (74% [95% CI, 46%–91%]), and ¹²³/¹³¹I-MIBG scan (38% [95% CI, 20%–59%], $P < 0.001$ for all). A greater prevalence of head and neck paragangliomas was associated with higher detection rates of ⁶⁸Ga-DOTA-SST PET ($P = 0.0002$). **Conclusion:** ⁶⁸Ga-DOTA-SST PET exhibited superior performance for lesion detection, over other functional imaging modalities, in patients with PPGLs, with the exception of polycythemia/paraganglioma syndrome. This might suggest ⁶⁸Ga-DOTA-SST PET as a first-line imaging modality for the primary staging of PPGL or the restaging of PPGL with unknown genetic status.

Key Words: ⁶⁸Ga-DOTATATE; ⁶⁸Ga-DOTATOC; ⁶⁸Ga-DOTANOC; pheochromocytoma; paraganglioma

Pheochromocytomas and paragangliomas (PPGLs) are tumors arising from sympathetic lineage-derived cells in adrenal medulla and extraadrenal thoracic and abdominal paraganglia or from the parasympathetic nervous system in the head and neck (1). Functional imaging plays an important role in the confirmation of diagnosis, staging or restaging, selection of targeted radionuclide therapy, and response evaluation in patients with PPGLs (2). ¹⁸F-fluorohydroxyphenylalanine (¹⁸F-FDOPA) PET is one of the standard diagnostic work-up for nonmetastatic PPGLs in the current guidelines (2–4). In a metaanalysis, the pooled lesion-based sensitivity and specificity of ¹⁸F-FDOPA PET were 79% and 95%, respectively (5). However, the diagnostic performance of ¹⁸F-FDOPA PET is largely influenced by tumor location and genetic status (6). ¹⁸F-FDG PET is recommended in metastatic PPGLs with succinate dehydrogenase A–D (collectively, *SDHx*) mutation and unknown or negative genetic mutations (2,3). A previous metaanalysis showed that the pooled sensitivity and specificity of ¹⁸F-FDG PET for metastatic PPGLs at a per-lesion level is 83% and 74%, respectively (7). ¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) scintigraphy has excellent sensitivity and specificity on a per-patient basis (8,9); however, its lesion-based diagnostic accuracy is limited (2).

Because PPGLs express high levels of somatostatin receptor (SSTR) (10–12), ⁶⁸Ga-DOTA–conjugated somatostatin receptor–targeting peptides (⁶⁸Ga-DOTA-SST) PET have shown an excellent lesion-based accuracy in detection of PPGLs (13–21). Recent publications suggest that ⁶⁸Ga-DOTA-SST PET provides a high detection rate across a wide range of mutations (22–25). However, because of the small number of subjects in individual studies, it is difficult to conclude a higher level of evidence.

Therefore, we performed a systematic review and metaanalysis to evaluate the performance of ⁶⁸Ga-DOTA-SST PET for lesion detection in patients with PPGLs.

MATERIALS AND METHODS

This systematic review and metaanalysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines

(26). The protocol was registered to the International Prospective Register of Systematic Reviews (registration no. CRD42018085906). The research question for this metaanalysis was as follows: "What is the performance of ^{68}Ga-DOTA-SST PET for lesion detection in patients with PPGL, compared with histopathologic results or best value comparator (BVC; a combination of imaging, clinical, or biologic studies)?"

Search Strategy

A computerized search on PubMed and Embase databases was performed until May 8, 2018. The search query included key words of "pheochromocytoma/paraganglioma," "^{68}Ga-DOTA-SST PET," and their related terms, as follows: (paraganglioma OR paragangliomas OR paragangliom* OR pheochromocytoma OR pheochromocytomas OR pheochromocytoma* OR feochromocytoma*) AND (Gallium OR Ga) AND (DOTA* OR somatostatin) AND ("PET" OR PET). Reference lists of the retrieved articles were also checked to identify additional relevant articles. The search was not limited to any particular language.

Study Selection

Studies were included based on "Patient/Intervention/Comparator/Outcome/Study design" (PICOS) criteria (26): (1) "patients" with PPGL, (2) ^{68}Ga-DOTA-SST PET as "intervention," (3) histopathology or BVC as "comparator," (4) detection rate as "outcome," and (5) "study design" as original articles. The following exclusion criteria were applied: (1) population $\leq$ 5; (2) nonoriginal articles; (3) papers irrelevant to the research question; and (4) overlapping study populations. When study populations overlapped, we selected the publication with the largest population for the metaanalysis. Two independent reviewers performed the literature search and selection process. Disagreement was resolved via discussion.

Data Extraction and Quality Assessment

Study and clinicopathologic characteristics were extracted using a standardized form. The methodologic quality of included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool (27). Data extraction and quality assessment were independently performed by 2 reviewers; any disagreements were resolved by discussion.

Data Synthesis and Analysis

The primary outcome was per-lesion detection rate of ^{68}Ga-DOTA-SST PET in patients with PPGLs. The secondary outcome was a comparison of the pooled estimates with those of other functional imaging modalities (^{18}F-FDOPA PET, ^{18}F-FDG PET, or MIBG scintigraphy) and to assess heterogeneity among the included articles.

The detection rate for each study was based on proportions reported in the study or calculated on the basis of the number of total lesions and number of lesions detected on PET. Of note, we recalculated the detection rate in one study after excluding one patient with medullary thyroid cancer (18). One study assessed metastasis on a per-site basis; it was analyzed on a per-lesion basis because the sites were subdivided into abdomen, bones, liver, lungs, and mediastinum (15).

The proportions were metaanalytically pooled using random-effects models with logit transformation. Statistical analyses were performed using "meta" and "metafor" packages in R software (version 3.4.3; R Foundation for Statistical Computing). Publication bias was evaluated with the funnel plot and Egger's test (28). Heterogeneity was evaluated by the Higgins I^2 test (29). Subgroup analyses and metaregression were performed to investigate the possible causes of heterogeneity using several clinically relevant covariates.

RESULTS

Literature Search

The detailed study selection process is shown in Figure 1. A total of 382 articles were retrieved by the initial systematic search. After the removal of 93 duplicate articles and exclusion of 261 papers during screening of the titles and abstracts, there were 28 potentially eligible articles. Full-text reviews were performed, and 15 were excluded for the following reasons: neuroendocrine tumor other than PPGL (n = 7) (30–35), population $\leq$ 5 (n = 3) (36–38), overlapping study population (n = 2) (39,40), insufficient information for detection rate (n = 1) (41), and nonoriginal articles (n = 3) (42–44). Thus, 13 studies were included in the qualitative synthesis. We further excluded 4 studies that had exclusive patient populations: *SDHB* mutation (22), *SDHx* mutation in pediatric patients (24), sporadic type (23), and polycythemia/paraganglioma syndrome (45); inclusion of those studies might hinder generalization of the results. Therefore, 9 studies (215 patients) with no specific inclusion criteria for subtype were included in the metaanalysis (13–21), with the assumption that this pooled population might reflect patients with unknown genetic status in clinical practice.

Characteristics of Included Studies

Study and clinicopathologic characteristics are described in Tables 1 and 2, respectively. Seven studies used histopathology and BVC as the reference standard (13,17–21,45), whereas 6 used only BVC (14–16,22–24).


FIGURE 1. Flow diagram showing study selection process.

TABLE 1
Study Characteristics

First author	Publication year	Design		Reference standard			Radioligand
		Prospective	Consecutive enrolment	Method	Details of BVC	Time interval	
Archier (13)	2016	Yes	NR	Histology+BVC	CT/MRI/FDOPA PET	<2 mo	DOTATATE
Chang (14)	2016	No	Yes	BVC	CT/FDG PET/MIBG scan*	NR	DOTATATE
Janssen (15)	2016	Yes	Yes	BVC	CT/MRI/FDOPA PET	<3 mo.	DOTATATE
Kroiss (16)	2011	No	NR	BVC	CT/MRI	<3 mo.	DOTATOC
Kroiss (17)	2013	No	NR	Histology+BVC	CT	<3 mo.	DOTATOC
Naji (18)	2011	No	NR	Histology+BVC	CT/MRI/FDG PET	<6 mo.	DOTATATE
Sharma (19)	2013	No	Yes	Histology+BVC	Clinical/biochemical/ imaging follow-up > 6 mo	NR	DOTANOC
Sharma (20)	2014	No	Yes	Histology+BVC	Clinical/biochemical/ imaging follow-up > 6 mo	NR	DOTANOC
Tan (21)	2015	Yes	Yes	Histology+BVC	CT/MRI/FDG PET/^{131}I-MIBG scan	<3 mo.	DOTATATE
Janssen (22)	2015	Yes	Yes	BVC	CT/MRI/FDG PET/ FDOPA PET (positive on ≥ 2 modalities)	22 ± 15 d.	DOTATATE
Janssen (23)	2016	Yes	Yes	BVC	CT/MRI/FDG PET/ FDOPA PET (positive on ≥ 2 modalities)	8.5 d. (median)	DOTATATE
Janssen (45)	2017	Yes	Yes	Histology+BVC	Clinical/imaging follow-up	31 ± 43 d.	DOTATATE
Jha (24)	2018	No	Yes	BVC	CT/MRI/FDG PET	3 d. (median)	DOTATATE

*[123]I-MIBG SPECT/CT (n = 7) and [124]I-MIBG PET/CT (n = 1).
NR = not reported.

The imaging modalities used for BVC included CT, MRI, ^{18}F-FDG PET, ^{18}F-FDOPA PET, and MIBG scintigraphy. ^{68}Ga-DOTA-SST PET was performed for primary staging in 4 (15,18–20), restaging in 2 (22,45), and staging or restaging in 7 studies (13,14,16,17,21,23,24). Radioligands were DOTATATE in 9 (13–15,18,21–24,45), DOTATOC in 2 (16,17), and DOTANOC in 2 studies (19,20).

Quality Assessment

The quality of the studies was considered moderate to good, with 12 of 13 studies satisfying at least 4 of the 7 QUADAS-2 domains (Fig. 2). Regarding the patient selection domain, 3 studies had an unclear risk of bias because they were retrospective, and it was not reported whether patients were consecutively enrolled (16–18). There was a high concern of applicability in 4 studies, as they only included patients with a specific genetic status or phenotypic subtype (15,22,24,45). Regarding the index test domain, there was an unclear risk of bias in 3 studies, as it was unclear whether the index test was interpreted without knowledge of the reference standard (14,18,21). For all studies, the concern for applicability was low. Regarding the reference standard domain, 4 studies showed an unclear risk of bias, as it was unclear whether

reference standard interpretation was masked to the index test results (14,19–21). There was an unclear concern for applicability in 10 studies because the BVCs were solely based on imaging modalities, without clinical or biochemical follow-up (13–18,21–24). Regarding the flow and timing domain, 3 studies had an unclear risk of bias, as the PET–reference standard interval was not provided (14,19,20).

Qualitative Synthesis

The detection rates of ^{68}Ga-DOTA-SST PET and other imaging modalities (^{18}F-FDOPA PET, ^{18}F-FDG PET, and [123/131]I-MIBG scanning) are illustrated in Figure 3. ^{68}Ga-DOTA-SST PET consistently showed a higher detection rate than ^{18}F-FDOPA PET, ^{18}F-FDG PET, and [123/131]I-MIBG scintigraphy, with the exception of one study regarding polycythemia/paraganglioma syndrome (45). In that study, ^{68}Ga-DOTA-SST PET showed the lowest detection rate of 35% (95% confidence interval [CI], 24%–48%), whereas the detection rate for ^{18}F-FDOPA PET was 99% (95% CI, 93%–100%). In the studies included, patients with *SDHx* mutation (22,24) and sporadic type (15), ^{68}Ga-DOTA-SST PET showed the highest detection rates among the functional imaging modalities.

TABLE 2
Clinicopathologic Characteristics

First author	Patients (n)	Mean age (y)	Subtype	Setting	Pheochromocytoma (n)	Paraganglioma (n)		Multifocal/Metastatic (n)	Catecholamine-secretory (n)	Genetic mutation (n)				Tumor size (cm)
						T&A	H&N			SDHx	Others	Sporadic	Not tested	
Archier (13)	30	53	No	S+R	11	0	20	7	NR	8	*MAX*: 1	21	0	2.0
Chang (14)	23	43	No	S+R	8	7	8	19	12	10	0	3	9	NR
Janssen (15)	20	48	No	S	0	0	20	17	12	16	*HIF2A*: 1	3	0	2.2
Kroiss (16)	6	46	No	S+R	5	1	0	6	NR	NR	NR	NR	6	NR
Kroiss (17)	20	50	No	S+R	0	3	19	5	NR	NR	NR	NR	20	NR
Naji (18)	11	NR	No	S	7	2	2	2	NR	4	0	1	6	1.8
Sharma (19)	26	34	No	S	0	0	26	15	4	NR	NR	NR	26	3.4
Sharma (20)	62	34	No	S	62	0	0	7	54	NR	NR	NR	62	4.1
Tan (21)	17	40†	No	S+R	10	NR	NR	15	9	NR	NR	NR	17	NR
Janssen (22)	17	40	*SDHB* mutation	R	2	10	5	17	11	17	0	0	0	NR
Janssen (23)	22	50	Sporadic	S+R	13	9	0	22	19	0	0	22	0	NR
Janssen (45)	13	37	PPGL– polycythemia	R	7	7	0	4	13	0	*HIF2A*: 6	6	0	NR
											PHD: 2			
Jha (24)	9	17	*SDHx* mutation	S+R	1	6	2	9	7	9	0	0	0	NR

HIF2A = hypoxia-inducible factor 2A; H&N = head and neck; *MAX* = MYC-associated factor X; NR = not reported; *PHD* = prolyl hydroxylase; PPGL = pheochromocytoma and paraganglioma; R = restaging; S = staging; *SDH* = succinate dehydrogenase; T&A = thorax and abdomen.
*Multiple endocrine neoplasia type 2.
†Median.

FIGURE 2. Quality assessment of 13 included studies.

FIGURE 4. Forest plot showing pooled proportion of detection rate of ^{68}Ga-DOTA-SST PET.

Quantitative Synthesis

The per-lesion detection rate in 9 studies included in the quantitative synthesis ranged from 92% to 100%, with a pooled estimate of 93% (95% CI, 91%–95%) (Fig. 4). On the basis of the Higgins I^2 statistics ($I^2 = 26\%$), no significant heterogeneity was present. There was significant publication bias, according to the funnel plot and Egger's test ($P = 0.0809$) (Supplemental Fig. 1; supplemental materials are available at http://jnm.snmjournals.org). The pooled detection rate of ^{68}Ga-DOTA-SST PET was significantly higher than that of ^{18}F-FDOPA PET (80% [95% CI, 69%–88%], $P = 0.0003$), ^{18}F-FDG PET (74% [95% CI, 46%–91%], $P < 0.0001$), or $^{123/131}$I-MIBG scintigraphy (38% [95% CI, 20%–59%], $P < 0.0001$). There was no difference in the detection rates of ^{68}Ga-DOTA-SST PET among the multiple subgroups stratified by reference standard, clinical setting, or radioligand (Table 3). A greater proportion of head and neck paragangliomas was significantly associated with higher detection rates of ^{68}Ga-DOTA-SST PET ($P = 0.0002$), whereas other variables, including the proportions of multifocal or metastatic disease, *SDHx* mutation, sporadic type, catecholamine-secretory PPGLs, age, and tumor size, were not significant in metaregression analyses (Fig. 5; Table 4).

DISCUSSION

In the present systematic review and metaanalysis, we evaluated the performance of ^{68}Ga-DOTA-SST PET for lesion detection in patients with PPGLs. The pooled detection rate was 93%, which was significantly higher than the detection rates of other functional imaging modalities. Accurate lesion detection is important for PPGLs, as these are typically surgically amenable; complete resection of lesions is needed, especially for catecholamine-secreting tumors.

^{18}F-FDOPA PET is one of the standard imaging modalities in nonmetastatic PPGLs (*2–4*). However, the difficulty in synthesis and the requirement of a nearby cyclotron precludes the wider use of ^{18}F-FDOPA. Furthermore, the diagnostic performance of ^{18}F-FDOPA PET is lower in extraadrenal paraganglioma and *SDHx*-related metastatic disease (*6*). The role of ^{18}F-FDG PET in PPGLs is limited for metastatic disease. MIBG scintigraphy requires complicated patient preparation (including thyroid blockade and discontinuation of certain drugs) and a long delay between injection and imaging. ^{123}I might not be available in every facility, whereas ^{131}I suffers from low image quality and unfavorable dosimetry. In contrast, ^{68}Ga-DOTA-SST PET imaging exhibits both practical advantages (no patient preparation, easy synthesis, and wide availability due to ^{68}Ge/^{68}Ga generator) and superior detection rates, relative to any other functional imaging modalities. The high cost of ^{68}Ge/^{68}Ga generators can be a potential drawback of ^{68}Ga-DOTA-SST PET imaging. However, increasing demand for ^{68}Ga-labeled radiotracers and recent approval of the SST analog kit by the U.S. Food and Drug Administration will make ^{68}Ge/^{68}Ga generators more readily available. Further, more effective planning, such as imaging centralization and a referral system, would help reduce the cost of ^{68}Ga imaging.

FIGURE 3. Comparison of detection rates among functional imaging modalities in 13 included studies.

**FIGURE 5.** Bubble plot for detection rate of ^{68}Ga-DOTA-SST PET and the proportion of head and neck paragangliomas shows that it is a significant factor affecting heterogeneity ($P = 0.0002$).

TABLE 3
Subgroup Analyses for Detection Rates

Variable	No. of studies	Detection rate (%)	95% CI (%)	I² (%)	P
Reference					0.7842
Histology+BVC	6	93	89–95	14	
BVC	3	95	88–98	52	
Setting					0.1412
Staging	4	96	88–99	44	
Staging+restaging	5	93	90–95	14	
Radioligands					0.5924
DOTATATE	5	94	90–96	27	
DOTATOC	2	95	76–99	52	
DOTANOC	2	97	72–100	67	

NA = not applicable.

For metaanalysis, we excluded 4 studies that exclusively included patients with specific subtypes. If we assume that the study samples included in our quantitative synthesis are representative of a PPGL population with unknown genetic status, it may be suggested that ^{68}Ga-DOTA-SST PET can serve as a first-line imaging modality for the primary staging of PPGLs, or the restaging of PPGLs with unknown genetic status. However, in 4 of the included studies (13–15,18), a substantial portion of patients was found to have the *SDHx* mutation; these proportions ranged from 27% to 80%, which are higher than the proportions in general PPGL populations (46). A higher prevalence of multifocal or metastatic disease, which is related to *SDHx* mutation, was also observed. Therefore, caution is necessary regarding the general application of our pooled estimate. On the basis of on our metaregression analyses, the performance of ^{68}Ga-DOTA-SST PET may not be affected by the prevalence of metastasis, *SDHx* mutation, or sporadic type. Our study also suggested that ^{68}Ga-DOTA-SST PET might exhibit a superior detection rate relative to ^{18}F-FDOPA or ^{18}F-FDG PET and serve as a functional imaging modality of choice in PPGLs with metastasis, *SDHx* mutation, or sporadic type.

^{68}Ga-DOTA-SST ligands have the highest affinity for SSTR2, with different affinities for other SSTR subtypes (12). ^{68}Ga-DOTATATE predominantly binds to SSTR2, ^{68}Ga-DOTATOC binds to SSTR2 and SSTR5, and ^{68}Ga-DOTANOC has a high affinity throughout SSTR2–5. No difference in detection performance was observed between the radioligands in our subgroup analysis; however, the low number of studies limited its significance. Of note, higher detection rates of ^{68}Ga-DOTA-SST PET were reported in studies that showed greater prevalence of head and neck paragangliomas. These tumors are parasympathetic in origin and usually do not secrete catecholamine; thus, they differ from pheochromocytomas or paragangliomas in the thorax and abdomen (1). Our findings are consistent with the recent guideline that recommends ^{68}Ga-DOTA-SST PET as the first-line imaging tool for head and neck paraganglioma (4). We suspect that the difference in overexpressed SSTR subtypes between the 2 kinds of PPGLs might affect the diagnostic performance of ^{68}Ga-DOTA-SST PET. Paragangliomas overexpress SSTR2 predominantly (11,12), whereas a single in vitro study showed that pheochromocytomas overexpress SSTR3 predominantly and SSTR2 to a lesser extent (10).

It should be noted that ^{68}Ga-DOTATATE showed poor diagnostic performance in patients presenting with polycythemia/paraganglioma syndrome, whereas ^{18}F-FDOPA PET exhibited the highest detection rate (45). The reason for this disparate diagnostic performance remains unclear; however, we speculate that a lack of SSTR expression, inactivation of SSTR, or overexpression of other SSTR subtypes (non-SSTR2) could explain such behavior. Similarly, in a recent study by Taieb et al. (38), ^{68}Ga-DOTATATE PET showed an inferior lesion detection rate, compared with ^{18}F-FDOPA PET, in MYC-associated factor X–related pheochromocytoma; however, only 3 subjects were evaluated. Further research is needed to clarify these discrepancies.

TABLE 4
Results of Metaregression Analyses

Variable	No. of studies	Regression coefficient	95% CI	P
Multifocal/metastatic disease (%)	9	−0.0001	−0.0010–0.0008	0.8299
Head and neck paragangliomas (%)	8	0.0007	0.0003–0.0011	0.0002
SDHx mutation (%)	4	0.0010	−0.0006–0.0025	0.2146
Sporadic type (%)	4	−0.0010	−0.0025–0.0004	0.1748
Catecholamine-secretory tumors (%)	5	−0.0009	−0.0027–0.0009	0.3164
Mean age (y)	8	0.0006	−0.0045–0.0056	0.8248
Mean tumor size (cm)	5	0.0118	−0.0301–0.0537	0.5522

There are some limitations in our review. First, the number of included studies is small. Even after a systematic search without any language restriction, we could identify only 8 suitable studies for quantitative synthesis. Nevertheless, metaanalysis is an appropriate method to generate a higher level of evidence in rare diseases, such as PPGLs, for which large cohort studies are not feasible. Second, approximately half of the included studies were retrospective in nature. Pooling results based on predominantly retrospective studies might lead to overestimation of the outcomes. Third, there were heterogeneities in scanners, image acquisition, and reconstruction protocols among the studies. Lastly, our pooled estimates were not based on studies that assessed patients with specific genetic mutations. No genetic test was performed in half of the included studies in our quantitative synthesis. Therefore, our results might not be applicable to specific genetic subtypes of PPGLs.

CONCLUSION

[68Ga]-DOTA-SST PET demonstrated an excellent lesion detection rate in patients with PPGLs. The pooled detection rate of the 8 included articles was 93%, which was significantly higher than the detection rate of other functional imaging modalities. Greater prevalence of head and neck paragangliomas was associated with higher detection rates of [68Ga]-DOTA-SST PET. However, in patients with polycythemia/paraganglioma syndrome, [68Ga]-DOTA-SST PET exhibited a poor detection rate.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. *Nat Rev Cancer.* 2014;14:108–119.
2. Taïeb D, Timmers HJ, Hindié E, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging.* 2012;39:1977–1995.
3. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2014;99:1915–1942.
4. Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with [68Ga]-DOTA-conjugated somatostatin receptor targeting peptides and [18F]–DOPA. *Eur J Nucl Med Mol Imaging.* 2017;44:1588–1601.
5. Treglia G, Cocciolillo F, De Waure C, et al. Diagnostic performance of [18F]-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. *Eur J Nucl Med Mol Imaging.* 2012;39:1144–1153.
6. Taïeb D, Tessonnier L, Sebag F, et al. The role of [18F]-FDOPA and [18F]-FDG-PET in the management of malignant and multifocal phaeochromocytomas. *Clin Endocrinol (Oxf).* 2008;69:580–586.
7. Kan Y, Zhang S, Wang W, Liu J, Yang J, Wang Z. [68Ga]-somatostatin receptor analogs and [18F]-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. *Acta Radiol.* 2018;1:284185118764206.
8. Van Der Horst-Schrivers AN, Jager PL, Boezen HM, Schouten JP, Kema IP, Links TP. Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas–experience and meta-analysis. *Anticancer Res.* 2006;26:1599–1604.
9. Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. ^{123}I-meta-iodobenzyl-guanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. *J Clin Endocrinol Metab.* 2010;95:2596–2606.
10. Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. *J Clin Endocrinol Metab.* 2003;88:5150–5157.
11. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. *Eur J Nucl Med.* 2001;28:836–846.
12. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. *Endocr Rev.* 2003;24:389–427.
13. Archier A, Varoquaux A, Garrigue P, et al. Prospective comparison of [68Ga]-DOTATATE and [18F]-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. *Eur J Nucl Med Mol Imaging.* 2016;43:1248–1257.
14. Chang CA, Pattison DA, Tothill RW, et al. [68Ga]-DOTATATE and [18F]-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. *Cancer Imaging.* 2016;16:22.
15. Janssen I, Chen CC, Taieb D, et al. [68Ga]-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. *J Nucl Med.* 2016;57:186–191.
16. Kroiss A, Putzer D, Uprimny C, et al. Functional imaging in phaeochromocytoma and neuroblastoma with [68Ga]-DOTA-Tyr 3-octreotide positron emission tomography and ^{123}I-metaiodobenzylguanidine. *Eur J Nucl Med Mol Imaging.* 2011;38:865–873.
17. Kroiss A, Putzer D, Frech A, et al. A retrospective comparison between [68Ga]-DOTA-TOC PET/CT and [18F]-FDOPA PET/CT in patients with extra-adrenal paraganglioma. *Eur J Nucl Med Mol Imaging.* 2013;40:1800–1808.
18. Naji M, Zhao C, Welsh SJ, et al. [68Ga]-DOTA-TATE PET vs. ^{123}I-MIBG in identifying malignant neural crest tumours. *Mol Imaging Biol.* 2011;13:769–775.
19. Sharma P, Thakar A, Suman S KC, et al. [68Ga]-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. *J Nucl Med.* 2013;54:841–847.
20. Sharma P, Dhull VS, Arora S, et al. Diagnostic accuracy of [68Ga]-DOTANOC PET/CT imaging in pheochromocytoma. *Eur J Nucl Med Mol Imaging.* 2014;41:494–504.
21. Tan TH, Hussein Z, Saad FF, Shuaib IL. Diagnostic performance of [68Ga]-DOTA-TATE PET/CT, [18F]-FDG PET/CT and ^{131}I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma. *Nucl Med Mol Imaging.* 2015;49:143–151.
22. Janssen I, Blanchet EM, Adams K, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. *Clin Cancer Res.* 2015;21:3888–3895.
23. Janssen I, Chen CC, Millo CM, et al. PET/CT comparing [68Ga]-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging.* 2016;43:1784–1791.
24. Jha A, Ling A, Millo C, et al. Superiority of [68Ga]-DOTATATE over [18F]-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (*SDHx*)-related pheochromocytoma and paraganglioma in the pediatric population. *Eur J Nucl Med Mol Imaging.* 2018;45:787–797.
25. Hofman MS, Lau WFE, Hicks RJ. Somatostatin receptor imaging with [68Ga] DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. *Radiographics.* 2015;35:500–516.
26. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;6:e1000097.
27. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med.* 2011;155:529–536.
28. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ.* 1997;315:629–634.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327:557–560.
30. Abongwa C, Mott S, Schafer B, et al. Safety and accuracy of [68Ga]-DOTATOC PET/CT in children and young adults with solid tumors. *Am J Nucl Med Mol Imaging.* 2017;7:228–235.
31. Berzaczy D, Giraudo C, Haug AR, et al. Whole-body [68Ga]-DOTANOC PET/MRI versus [68Ga]-DOTANOC PET/CT in patients with neuroendocrine tumors: a prospective study in 28 patients. *Clin Nucl Med.* 2017;42:669–674.
32. Goel R, Shukla J, Bansal D, et al. [68Ga]-DOTATATE positron emission tomography/computed tomography scan in the detection of bone metastases in pediatric neuroendocrine tumors. *Indian J Nucl Med.* 2014;29:13–17.

33. Lawal IO, Ololade KO, Lengana T, et al. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: first experience in Africa. *Hell J Nucl Med.* 2017;20:128–133.

34. Sharma P, Arora S, Mukherjee A, et al. Predictive value of ^{68}Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified? *Clin Nucl Med.* 2014;39:37–43.

35. Sharma P, Mukherjee A, Karunanithi S, et al. Accuracy of ^{68}Ga DOTANOC PET/CT imaging in patients with multiple endocrine neoplasia syndromes. *Clin Nucl Med.* 2015;40:e351–e356.

36. Kornaczewski ER, Pointon OP, Burgess JR. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions. *Clin Endocrinol (Oxf).* 2016;85:172–179.

37. Win Z, Al-Nahhas A, Towey D, et al. ^{68}Ga-DOTATATE PET in neuroectodermal tumours: first experience. *Nucl Med Commun.* 2007;28:359–363.

38. Taïeb D, Jha A, Guerin C, et al. ^{18}F-FDOPA PET/CT imaging of MAX-related pheochromocytoma. *J Clin Endocrinol Metab.* 2018;103:1574–1582.

39. Kroiss A, Shulkin BL, Uprimny C, et al. ^{68}Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to ^{123}I-MIBG SPECT/CT. *Eur J Nucl Med Mol Imaging.* 2015;42: 33–41.

40. Naswa N, Sharma P, Nazar AH, et al. Prospective evaluation of ^{68}Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. *Eur Radiol.* 2012;22:710–719.

41. Jing H, Li F, Wang L, et al. Comparison of the ^{68}Ga-DOTATATA PET/CT, FDG PET/CT, and MIBG SPECT/CT in the evaluation of suspected primary pheochromocytomas and paragangliomas. *Clin Nucl Med.* 2017;42:525–529.

42. Maurice JB, Troke R, Win Z, et al. A comparison of the performance of ^{68}Ga-DOTATATE PET/CT and ^{123}I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging.* 2012;39: 1266–1270.

43. Naswa N, Kumar A, Sharma P, Bal C, Malhotra A, Kumar R. Imaging carotid body chemodectomas with ^{68}Ga-DOTA-NOC PET-CT. *Br J Radiol.* 2012;85:1140–1145.

44. Şimşek DH, Şanlı Y, Kuyumcu S, Başaran B, Mudun A. ^{68}Ga-DOTATATE PET–CT imaging in carotid body paragangliomas. *Ann Nucl Med.* 2018;32:297–301.

45. Janssen I, Chen CC, Zhuang Z, et al. Functional imaging signature of patients presenting with polycythemia/paraganglioma syndromes. *J Nucl Med.* 2017;58: 1236–1242.

46. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. *Lancet.* 2005;366:665–675.